the occurrence of al in multiple myeloma , lymphomas , other malignancies , and in nonmalignant diseases following treatment with myelosuppressive agents , forces one to consider the leukemogenic potential of any agent capable of suppressing the panmyelopathy of this disease , as well as the inherent tendency to al of the `` '' untreated '' '' disease .
C0024299
lymphomas
C0006826
malignancies